头孢吡肟在接受连续肾脏替代治疗的危重症儿科患者中的药代动力学。
Cefepime Pharmacokinetics in Critically Ill Pediatric Patients Receiving Continuous Renal Replacement Therapy.
机构信息
Department of Pharmacy Services, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
Department of Pharmacy Services, Texas Children's Hospital, Houston, Texas, USA.
出版信息
Antimicrob Agents Chemother. 2019 Mar 27;63(4). doi: 10.1128/AAC.02006-18. Print 2019 Apr.
Abstract
This retrospective study included pediatric intensive care unit patients receiving continuous veno-venous hemodiafiltration (CVVHDF) being treated with cefepime. The free drug concentration above one time the MIC (>1×MIC) and four times a presumed MIC (>4×MIC) of 8 μg/ml were calculated. Four patients received doses ranging from 48 to 64 mg/kg of body weight every 6 to 12 h. Three patients achieved 100% >1×MIC, with the fourth patient achieving 98% >1×MIC. Therapeutic drug monitoring should be considered for critically ill patients receiving cefepime on CVVHDF.
摘要
这项回顾性研究纳入了接受连续性静脉-静脉血液透析滤过（CVVHDF）治疗并使用头孢吡肟的儿科重症监护病房患者。计算游离药物浓度超过最低抑菌浓度（MIC）1 倍（>1×MIC）和 4 倍（>4×MIC），分别为 8μg/ml 和 32μg/ml。4 名患者每 6 至 12 小时接受 48 至 64mg/kg 的剂量。3 名患者达到 100%>1×MIC，第 4 名患者达到 98%>1×MIC。接受 CVVHDF 治疗头孢吡肟的危重症患者应考虑进行治疗药物监测。
相似文献
1
Cefepime Pharmacokinetics in Critically Ill Pediatric Patients Receiving Continuous Renal Replacement Therapy.头孢吡肟在接受连续肾脏替代治疗的危重症儿科患者中的药代动力学。
Antimicrob Agents Chemother. 2019 Mar 27;63(4). doi: 10.1128/AAC.02006-18. Print 2019 Apr.
2
Pharmacokinetics and Pharmacodynamics of Extended-Infusion Cefepime in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Prospective, Open-Label Study.连续肾脏替代治疗的危重症患者中头孢吡肟延长输注的药代动力学和药效学：一项前瞻性、开放标签研究。
Pharmacotherapy. 2019 Nov;39(11):1066-1076. doi: 10.1002/phar.2332. Epub 2019 Oct 22.
3
Applying Cefepime Population Pharmacokinetics to Critically Ill Patients Receiving Continuous Renal Replacement Therapy.将头孢吡肟群体药代动力学应用于接受连续肾脏替代治疗的危重症患者。
Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0161121. doi: 10.1128/AAC.01611-21. Epub 2021 Oct 18.
4
Pharmacokinetics and Time above the MIC Exposure of Cefepime in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO).接受体外膜肺氧合（ECMO）治疗的危重症患者中头孢吡肟的药代动力学和 MIC 以上暴露时间。
Int J Antimicrob Agents. 2022 Jul;60(1):106603. doi: 10.1016/j.ijantimicag.2022.106603. Epub 2022 May 14.
5
Cystatin C Outperforms Creatinine in Predicting Cefepime Clearance in Pediatric Stem Cell Transplant Recipients.胱抑素C在预测儿科干细胞移植受者头孢吡肟清除率方面优于肌酐。
Transplant Cell Ther. 2024 Jun;30(6):614.e1-614.e11. doi: 10.1016/j.jtct.2024.03.021. Epub 2024 Mar 22.
6
Population pharmacokinetics of cefepime in critically ill patients receiving extracorporeal membrane oxygenation (an ASAP ECMO study).接受体外膜肺氧合（ASAP ECMO 研究）的危重症患者中头孢吡肟的群体药代动力学。
Int J Antimicrob Agents. 2021 Dec;58(6):106466. doi: 10.1016/j.ijantimicag.2021.106466. Epub 2021 Oct 21.
7
Cefepime pharmacokinetics in critically ill children and young adults undergoing continuous kidney replacement therapy.头孢吡肟在接受连续肾脏替代治疗的危重症儿童和青年中的药代动力学。
J Antimicrob Chemother. 2023 Sep 5;78(9):2140-2147. doi: 10.1093/jac/dkad192.
8
Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration.多利培南群体药代动力学及连续性静脉-静脉血液透析滤过危重症患者的给药需求。
J Antimicrob Chemother. 2014 Sep;69(9):2508-16. doi: 10.1093/jac/dku177. Epub 2014 May 30.
9
Once-daily 1 g ceftriaxone optimizes exposure in patients with septic shock and hypoalbuminemia receiving continuous veno-venous hemodiafiltration.对于接受连续性静脉-静脉血液透析滤过治疗的脓毒性休克伴低白蛋白血症患者，每日 1 克头孢曲松可优化其药物暴露。
Eur J Clin Pharmacol. 2021 Aug;77(8):1169-1180. doi: 10.1007/s00228-021-03100-5. Epub 2021 Feb 9.
10
Cefepime Population Pharmacokinetics and Target Attainment in Critically Ill Patients on Continuous Renal Replacement Therapy.头孢吡肟群体药代动力学及连续性肾脏替代治疗危重症患者的目标达成情况。
Antimicrob Agents Chemother. 2021 May 18;65(6). doi: 10.1128/AAC.00144-21.
引用本文的文献
1
Monte Carlo simulations of cefepime in children receiving continuous kidney replacement therapy support continuous infusions for target attainment.接受持续肾脏替代治疗的儿童中头孢吡肟的蒙特卡洛模拟支持持续输注以达到目标。
J Intensive Care. 2024 Oct 8;12(1):38. doi: 10.1186/s40560-024-00752-0.
2
Cystatin C Outperforms Creatinine in Predicting Cefepime Clearance in Pediatric Stem Cell Transplant Recipients.胱抑素C在预测儿科干细胞移植受者头孢吡肟清除率方面优于肌酐。
Transplant Cell Ther. 2024 Jun;30(6):614.e1-614.e11. doi: 10.1016/j.jtct.2024.03.021. Epub 2024 Mar 22.
3
Bioanalysis of six antibiotics from volumetric microsamples: a new tool for precision dosing in critically ill children.来自微量样本的六种抗生素的生物分析：危重症儿童精准给药的新工具
Bioanalysis. 2024 Jan;16(1):19-31. doi: 10.4155/bio-2023-0171. Epub 2023 Nov 22.
4
Cefepime pharmacokinetics in critically ill children and young adults undergoing continuous kidney replacement therapy.头孢吡肟在接受连续肾脏替代治疗的危重症儿童和青年中的药代动力学。
J Antimicrob Chemother. 2023 Sep 5;78(9):2140-2147. doi: 10.1093/jac/dkad192.
5
Cefepime Dosing in a Critically Ill Neonate Receiving Continuous Renal Replacement Therapy With the Cardio-Renal Pediatric Dialysis Emergency Machine (CARPEDIEM).在使用心肺肾儿科透析急救机器（CARPEDIEM）进行持续肾脏替代治疗的危重新生儿中头孢吡肟的给药剂量。
J Pediatr Pharmacol Ther. 2023;28(2):167-171. doi: 10.5863/1551-6776-28.2.167. Epub 2023 Apr 26.
6
Cefepime Extraction by Extracorporeal Life Support Circuits.体外生命支持回路对头孢吡肟的萃取。
J Extra Corpor Technol. 2022 Sep;54(3):212-222. doi: 10.1182/ject-212-222.
7
Antimicrobial Dosing Recommendations in Pediatric Continuous Renal Replacement Therapy: A Critical Appraisal of Current Evidence.儿童连续性肾脏替代治疗中的抗菌药物给药建议：对当前证据的批判性评价
Front Pediatr. 2022 May 12;10:889958. doi: 10.3389/fped.2022.889958. eCollection 2022.
8
Anti-infective Medicines Use in Children and Neonates With Pre-existing Kidney Dysfunction: A Systematic Review.已有肾功能不全的儿童和新生儿使用抗感染药物：一项系统评价
Front Pediatr. 2022 Apr 26;10:868513. doi: 10.3389/fped.2022.868513. eCollection 2022.
9
A Review of Extended and Continuous Infusion Beta-Lactams in Pediatric Patients.儿科患者中延长输注和持续输注β-内酰胺类药物的综述
J Pediatr Pharmacol Ther. 2022;27(3):214-227. doi: 10.5863/1551-6776-27.3.214. Epub 2022 Mar 21.
10
Pharmacokinetics of Commonly Used Medications in Children Receiving Continuous Renal Replacement Therapy: A Systematic Review of Current Literature.儿童连续肾脏替代治疗中常用药物的药代动力学：当前文献的系统评价。
Clin Pharmacokinet. 2022 Feb;61(2):189-229. doi: 10.1007/s40262-021-01085-z. Epub 2021 Nov 30.
本文引用的文献
1
Renal Replacement Therapy in the Critically Ill Child.危重症儿童的肾脏替代治疗。
Pediatr Crit Care Med. 2018 Mar;19(3):210-217. doi: 10.1097/PCC.0000000000001431.
2
Infection in critically ill pediatric patients on continuous renal replacement therapy.接受持续肾脏替代治疗的危重症儿科患者的感染情况。
Int J Artif Organs. 2017 May 29;40(5):224-229. doi: 10.5301/ijao.5000587. Epub 2017 May 18.
3
Predictive factors of mortality in pediatric patients with acute renal injury associated with sepsis.脓毒症相关急性肾损伤小儿患者死亡的预测因素
J Pediatr (Rio J). 2017 Jan-Feb;93(1):28-34. doi: 10.1016/j.jped.2016.04.006. Epub 2016 Jul 2.
4
Acute Kidney Injury Requiring Dialysis in Severe Sepsis.严重脓毒症需要透析的急性肾损伤。
Am J Respir Crit Care Med. 2015 Oct 15;192(8):951-7. doi: 10.1164/rccm.201502-0329OC.
5
Cefepime free minimum concentration to minimum inhibitory concentration (fCmin/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia.头孢吡肟游离最低浓度与最低抑菌浓度（fCmin/MIC）比值预测革兰氏阴性菌肺炎患者的临床失败。
Int J Antimicrob Agents. 2015 May;45(5):541-4. doi: 10.1016/j.ijantimicag.2014.12.018. Epub 2015 Jan 19.
6
DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients?DALI 研究：确定重症监护病房患者的抗生素水平：目前的β-内酰胺类抗生素剂量是否足以满足重症患者的需求？
Clin Infect Dis. 2014 Apr;58(8):1072-83. doi: 10.1093/cid/ciu027. Epub 2014 Jan 14.
7
Defining pediatric sepsis by different criteria: discrepancies in populations and implications for clinical practice.根据不同标准定义儿童脓毒症：人群差异及其对临床实践的影响。
Pediatr Crit Care Med. 2012 Jul;13(4):e219-26. doi: 10.1097/PCC.0b013e31823c98da.
8
Low cefepime concentrations during high blood and dialysate flow continuous venovenous hemodialysis.高血流和透析液流速持续静脉-静脉血液透析时头孢吡肟浓度较低。
Antimicrob Agents Chemother. 2012 Apr;56(4):2178-80. doi: 10.1128/AAC.05987-11. Epub 2012 Jan 30.
9
Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy.推荐的β-内酰胺方案在接受连续肾脏替代治疗的脓毒症患者中是不足够的。
Crit Care. 2011;15(3):R137. doi: 10.1186/cc10257. Epub 2011 Jun 6.
10
Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept.危重症患者β-内酰胺类药物的治疗药物监测：概念验证。
Int J Antimicrob Agents. 2010 Oct;36(4):332-9. doi: 10.1016/j.ijantimicag.2010.06.008. Epub 2010 Aug 3.
Zotero 插件